logo-loader
Shield Therapeutics PLC

Update on Legal Proceedings

/**/ sup{font-size:80%}h1{margin-top:12.0pt;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;font-size:16.0pt;font-family:"Calibri Light","sans-serif";color:#2F5496;border:none;font-weight:normal;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}link{ color: #000000 }visited{ color: #954F72 } .ae{size:595.3pt 841.9pt;margin:2.0cm 42.55pt 2.0cm 42.55pt;}div.ae{}p.bz{margin-top:2.2pt;margin-right:23.5pt;margin-bottom:0cm;margin-left:27.75pt;margin-bottom:.0001pt;text-align:center;font-size:14.0pt;font-family:"Calibri","sans-serif";color:black;border:none;font-weight:bold;margin-top:0cm;margin-right:-.1pt;margin-bottom:0cm; margin-left:0cm;margin-bottom:.0001pt}span.bx{font-size:11.0pt}p.ca{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";color:black;border:none;margin-right: -.1pt; text-align: center}p.cb{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";color:black;border:none;margin-right: 23.45pt; text-align: center}p.cc{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";border:none;font-weight: bold; text-align: center}span.bt{font-size:11.0pt;font-family:"Calibri","sans-serif"}p.cd{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";border:none;text-align:justify;border:none}strong.bq{font-div: italic} span.br{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black;font-weight:normal}span.bo{font-size:11.0pt; font-family:"Calibri","sans-serif";color:black}span.ce{font-family:"Calibri","sans-serif";color:windowtext;font-size:11.0pt}p.cf{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";border:none;text-align:justify}span.bm{font-family:"Calibri","sans-serif"}p.cg{margin-right:0cm;margin-left:0cm;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:0cm;text-align:justify}span.ch{font-family:"Calibri","sans-serif";color:windowtext;border:none}p.bj{font-weight: bold; margin: 0cm; margin-bottom: .0001pt; text-align: center}p.ci{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";color:black;border:none;font-weight: bold}p.h,li.h,div.h{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";color:black;border:none;} table.cj{width:515.7pt;margin-left:-10.8pt;border-collapse:collapse}td.bg{width:192.0pt;padding:0cm 5.4pt 0cm 5.4pt}p.ck{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";border:none;font-weight: bold}span.bh{font-size:11.0pt;font-family: "Calibri","sans-serif";color:black}td.bc{width:302.1pt;padding:0cm 5.4pt 0cm 5.4pt}p.cl{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";border:none;text-align: right}span.bf{font-size:11.0pt; font-family:"Calibri","sans-serif";color:blue;background:white}span.be{font-family: "Calibri","sans-serif"; font-size: 11.0pt; text-decoration: underline}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";border:none;}span.bb{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black} span.ba{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}span.az{font-family:"Calibri","sans-serif";color:black}span.ay{font-family:"Calibri","sans-serif"; color:black}p.cm{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";border:none;font-div: italic; font-weight: bold}.aw{font-div: italic}span.av{font-size:11.0pt;font-family: "Calibri","sans-serif"}p.cn{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";border:none;font-weight: bold; vertical-align: baseline}span.au{font-size:11.0pt;font-family:"Calibri","sans-serif";border:none windowtext 1.0pt; padding:0cm}p.co{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";border:none;vertical-align:baseline}span.ar{font-family:"Calibri","sans-serif";border:none windowtext 1.0pt; padding:0cm} span.aq{font-size:11.0pt;font-family:"Calibri","sans-serif";background:white}span.ap{font-size:11.0pt;font-family: "Calibri","sans-serif";color:blue;background:white}span.ao{font-size:11.0pt;font-family:"Calibri","sans-serif"; background:white}span.an{font-size:11.0pt; font-family:"Calibri","sans-serif"}p.ak{margin:0cm;margin-bottom:.0001pt;text-align:justify}span.al{font-size:11.0pt;font-family:"Calibri","sans-serif"; border:none}p.cp{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin: 0cm; margin-bottom: .0001pt}span.aj{font-size: 11.0pt;font-family:"Calibri","sans-serif";color:black}span.ah{font-size: 11.0pt;font-family:"Calibri","sans-serif";color:#0066CC}span.ag{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:#1F497D} p.cq{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify}span.cr{color: black; font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold} /**/
RNS Number : 8490A
Shield Therapeutics PLC
03 June 2019
 

Shield Therapeutics plc

("Shield" or the "Group")

 

Update on Legal Proceedings

 

London, UK, 3 June 2019:  Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with or without anaemia via its lead product Feraccru®, announces an update on legal proceedings with Teva Pharmaceutical Industries Ltd (TEVA).

 

Following the announcement to shareholders on 14 March 2019, Shield has received notice that TEVA has filed a notice of appeal to the Opposition Division of the European Patent Office's decision on Shield's patent #2 668 175, which covers a "Process for preparing an iron hydroxypyrone".  No date has been set for the hearing.

 

Shield will continue to robustly defend its intellectual property and believes the Board of Appeal should uphold the first instance decision of the European Patent Office.

 

Shield will provide further updates to shareholders on proceedings as required.

- Ends -

 

For further information please contact:

 

Shield Therapeutics plc

www.shieldtherapeutics.com

Carl Sterritt, Chief Executive Officer

+44 (0)20 7186 8500

Tim Watts, Chief Financial Officer




Nominated Advisor and Joint Broker


Peel Hunt LLP


James Steel/Dr Christopher Golden                                                

+44 (0)20 7418 8900



Joint Broker


finnCap Ltd

+44 (0)20 7220 0500

Geoff Nash /Matt Radley/ Alice Lane                                    




Financial PR & IR Advisor


Walbrook PR

+44 (0)20 7933 8780 or [email protected]

Paul McManus / Anna Dunphy

+44 (0)7980 541 893 / +44 (0)7876 741 001

 

About Shield Therapeutics plc

Shield is a de-risked, commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs.  The Company's clear purpose is to help its patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives.  The Group has a marketed product, Feraccru®, for the treatment of iron deficiency in adults which has exclusive IP rights until the mid-2030s.  Feraccru® is commercialised in the European Union by Norgine BV and the US Food and Drug Administration (FDA) is currently considering a New Drug Application (NDA), with a PDUFA (Prescription Drug User Fee Act) date of 27th July 2019.  For more information please visit www.shieldtherapeutics.com. 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
UPDDBGDLGDGBGCD

Quick facts: Shield Therapeutics PLC

Price: £1.79

Market: LSE
Market Cap: £209.18 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Shield Therapeutics 'in a strong position' and confident of a US Feraccru deal

Shield Therapeutics (LON:STX) chief financial officer Tim Watts talks Proactive London's Andrew Scott through their first half update to June 2019. ''If you consider where we've been over the last 12 months we're in a far, far stronger position now and with the US approval of Feraccru we're...

1 week, 3 days ago

RNS

Director/PDMR Shareholding

3 days, 6 hours ago

Half-year Report

1 week, 4 days ago

Notice of Results

2 weeks, 4 days ago

Second Price Monitoring Extn

3 weeks, 2 days ago

Price Monitoring Extension

3 weeks, 2 days ago

Additional Listing

on 2/7/19

Result of AGM

on 13/6/19